17:54 , Jan 11, 2019 |  BC Week In Review  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
03:04 , Jan 7, 2019 |  BC Extra  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:24 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead grows fibrosis pipeline with Scholar Rock deal

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to expand its fibrotic pipeline. Gilead received options to two...
23:42 , Dec 19, 2018 |  BC Extra  |  Company News

Gilead grows fibrosis pipeline with Scholar Rock deal

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to expand its fibrotic pipeline. Gilead received options to two...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
18:43 , Dec 5, 2018 |  BC Extra  |  Politics & Policy

FDA NASH guidance charts course for surrogate endpoints tied to biopsies

Four companies with products in Phase III testing to treat non-alcoholic steatohepatitis are well positioned to meet endpoints that could support accelerated approval, according to requirements outlined in new FDA draft guidance. However, the guidance...
19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
23:56 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes; obesity Patient sample, cell culture and mouse studies suggest inhibiting FXR with glycoursodeoxycholic acid could help treat obesity and obesity-related diabetes. In Type II diabetes patients receiving the generic diabetes drug metformin, serum...
18:16 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The...